Supernus Pharmaceuticals Inc (SUPN)
31.16
+0.70
(+2.30%)
USD |
NASDAQ |
May 07, 16:00
31.16
0.00 (0.00%)
After-Hours: 20:00
Supernus Pharmaceuticals Gross Profit Margin (Quarterly): 88.06% for Dec. 31, 2023
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 88.06% |
September 30, 2023 | 87.26% |
June 30, 2023 | 84.44% |
March 31, 2023 | 84.74% |
December 31, 2022 | 86.28% |
September 30, 2022 | 85.41% |
June 30, 2022 | 87.97% |
March 31, 2022 | 88.24% |
December 31, 2021 | 89.32% |
September 30, 2021 | 87.82% |
June 30, 2021 | 82.29% |
March 31, 2021 | 88.58% |
December 31, 2020 | 87.09% |
September 30, 2020 | 86.21% |
June 30, 2020 | 93.38% |
March 31, 2020 | 95.63% |
December 31, 2019 | 95.91% |
September 30, 2019 | 95.28% |
June 30, 2019 | 96.14% |
March 31, 2019 | 95.69% |
December 31, 2018 | 96.39% |
September 30, 2018 | 95.92% |
Date | Value |
---|---|
June 30, 2018 | 96.30% |
March 31, 2018 | 96.38% |
December 31, 2017 | 95.30% |
September 30, 2017 | 94.71% |
June 30, 2017 | 94.91% |
March 31, 2017 | 94.88% |
December 31, 2016 | 93.95% |
September 30, 2016 | 93.97% |
June 30, 2016 | 94.67% |
March 31, 2016 | 95.40% |
December 31, 2015 | 93.60% |
September 30, 2015 | 94.29% |
June 30, 2015 | 95.06% |
March 31, 2015 | 94.37% |
December 31, 2014 | 92.69% |
September 30, 2014 | 94.18% |
June 30, 2014 | 94.40% |
March 31, 2014 | 94.56% |
December 31, 2013 | 89.68% |
September 30, 2013 | 97.37% |
June 30, 2013 | 98.58% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
82.29%
Minimum
Jun 2021
96.14%
Maximum
Jun 2019
88.95%
Average
87.97%
Median
Jun 2022
Gross Profit Margin (Quarterly) Benchmarks
Dynavax Technologies Corp | 84.37% |
Ligand Pharmaceuticals Inc | 94.16% |
Pacira BioSciences Inc | 73.69% |
Esperion Therapeutics Inc | 64.49% |
Collegium Pharmaceutical Inc | 63.19% |
Gross Profit Margin (Quarterly) Related Metrics
Return on Equity | 0.14% |
Return on Assets | 0.09% |
Return on Invested Capital | 0.12% |
Profit Margin (Quarterly) | 0.72% |
Operating Margin (Quarterly) | 11.56% |
Return on Net Operating Assets | 0.13% |